News
ALGS
8.09
+1.51%
0.12
Weekly Report: what happened at ALGS last week (0330-0403)?
Weekly Report · 1d ago
Weekly Report: what happened at ALGS last week (0323-0327)?
Weekly Report · 03/30 09:37
Aligos Therapeutics Price Target Announced at $48.00/Share by WestPark Capital
Dow Jones · 03/26 14:25
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48
Benzinga · 03/26 14:15
Aligos Therapeutics initiated with a Buy at WestPark Capital
TipRanks · 03/26 13:00
Weekly Report: what happened at ALGS last week (0316-0320)?
Weekly Report · 03/23 09:35
Aligos Therapeutics Price Target Cut to $48.00/Share From $60.00 by Jefferies
Dow Jones · 03/19 19:50
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48
Benzinga · 03/19 19:40
Aligos Therapeutics assumed with a Buy at Jefferies
TipRanks · 03/19 09:15
Weekly Report: what happened at ALGS last week (0309-0313)?
Weekly Report · 03/16 09:35
Aligos Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 03/11 17:28
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target
Benzinga · 03/11 17:19
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF)
TipRanks · 03/11 16:40
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Cresco Labs (OtherCRLBF)
TipRanks · 03/09 15:50
Weekly Report: what happened at ALGS last week (0302-0306)?
Weekly Report · 03/09 09:36
Aligos Reports FY25 Results, Highlights Progress Across Liver And Viral Disease Pipeline
NASDAQ · 03/06 01:01
Aligos Therapeutics GAAP EPS of -$1.91 beats by $0.12
Seeking Alpha · 03/05 18:02
Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)
TipRanks · 03/05 13:14
Aligos Therapeutics Earnings Report: Q4 Overview
Benzinga · 03/05 13:14
Aligos Therapeutics Q4 net loss narrows
Reuters · 03/05 13:10
More
Webull provides a variety of real-time ALGS stock news. You can receive the latest news about Aligos Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.